Methyl nicotinate 1% cream
Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Methyl nicotinate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Methyl nicotinate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Methyl nicotinate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Tablets & capsules
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Randomised trials: 1 · 1981–2026
Showing the 50 most relevant studies, sorted by most relevant.
R. Sivamani, B. Stoeber, Gabriel C. Wu, et al.
Skin Research and Technology, 2005
- Needles
- Epidermis
- Skin
H. Pabst, A. Schaefer, C. Staiger, et al.
Phytotherapy Research, 2012
- Phytotherapy
- Comfrey
- Low Back Pain
C.E. Blom, Hs.H. Günthard
Chemical Physics Letters, 1981
Suzan Abuelhassan, A. E. Abdel-Rahman, M. Gad, et al.
Journal of agricultural and food chemistry, 2024
- Aphids
- Pyridines
- Insecticides
M. Vennila, R. Rathikha, S. Muthu, et al.
Computational and Theoretical Chemistry, 2022
John F. Black, Ivan Powis
Chemical Physics, 1988
Zhai K, Dong Z, Geng B, et al.
2025
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Gas Chromatography-Mass Spectrometry
Metabolomics has been applied in several studies on cancer, but few studies have screened potential biomarkers for renal cell carcinoma (RCC) by integrating two mass mass spectrometers. This study aims to identify differentially expressed metabolites in plasma samples from patients with RCC compared with healthy individuals, which could be used as potential biomarkers to detect RCC. Plasma samples from 48 patients diagnosed with RCC and 22 healthy individuals were analyzed. Two mass spectrometers were utilized: liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS). Ceramide m40:0 was significantly less abundant in plasma samples from patients with RCC (P < 0.05), whereas kynureine metabolites and glucose metabolites were significantly more abundant in plasma samples from patients with RCC compared with healthy controls (P < 0.05). A selection of 21 metabolites was utilized to construct an optimal diagnostic model, which achieved an area under the receiver operating characteristic curve (AUC) value of 0.860 (95% confidence interval 0.736-0.960). Significant differences were identified in the metabolic pathways of nicotinate and nicotinamide metabolism, pantothenate and coenzyme A biosynthesis, and beta-alanine metabolism between the RCC group and the control group (P < 0.05). The combined use of LC-MS and GC-MS effectively identified differentially expressed metabolites and dysregulated pathways based on analysis of plasma samples from patients with RCC compared with healthy individuals. The diagnostic model demonstrated robust performance with an AUC of 0.860, highlighting its reliability for RCC identification.
Abstract licence: CC BY-NC-ND
Mao Z
2025
Medvedkov IA, Yang Z, Goettl SJ, et al.
2025
Yang M, Liu X, Li R, et al.
2025
Flavor is a pivotal indicator influencing the meat quality and palatability of premium broiler chickens, shaped by multiple factors. The flavor differences among broiler chicken breeds/lines stem from the specificity of their metabolite profiles and volatile flavor compounds. This study aims to identify key metabolites and pathways that regulate flavor variations in high-quality broilers, providing data support and theoretical references for breeding superior broiler lines and developing technologies to enhance flavor quality. Breast Muscle tissue from 15-week-old roosters of the S3 and H lines (n = 6) was used as experimental material. Broad-targeted metabolomics and volatile metabolomics technologies were employed to identify key metabolites and volatile organic compounds (VOCs) influencing the flavor of breast meat in these two high-quality broiler lines. Broad-target metabolomics identified 167 differentially expressed metabolites (VIP > 1, p p 1 and p < 0.05). The flavor differences between the two strains primarily involved fatty and grassy flavor. Key flavor markers included 2-Nonanone, 2-Nonanone, 3-hydroxymethyl, 2-Methylheptanoic acid, and Hexanoic acid, butyl ester as the primary flavor markers. These significantly downregulated volatiles are formed through lipid oxidation and amino acid degradation pathways, respectively, collectively shaping the more pronounced fatty and grassy aromas in the S3 strain. Correlation analysis revealed a significant negative correlation between Met-Asn and Hexanoic acid, butyl ester, suggesting it may represent a key regulatory pathway influencing green flavor formation. In summary, this study elucidates key metabolites and pathways governing flavor differences in high-quality broiler rooster breast meat, providing a scientific foundation for poultry breeding, optimization of farming practices, and flavor regulation in meat products.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3 to 10 minutes
Mechanism
While the mechanism of action of methyl nicotinate and other topically-administe…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
80-90%
Half-life
3 to 10 minutes
[A33028]
Protein binding
Volume of distribution
Metabolism
Elimination
15%
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A33028]
[A33027]
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Methyl nicotinate
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72